Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine

NCT02638103 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1890

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: Fremanezumab
DRUG: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.